azenosertib (ZN-c3) / Zentalis Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
azenosertib (ZN-c3) / Zentalis Pharma
ZN-c3-004, NCT04814108: A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Active, not recruiting
2
76
Canada, US, RoW
ZN-c3, azenosertib, KP-2638
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Uterine Serous Carcinoma
11/24
05/25
NCT06369155: Azenosertib in Uterine Serous Carcinoma: Biomarker Study

Not yet recruiting
2
25
US
Azenosertib, Zn-c3, C29H34N8O2
Joyce Liu, MD, National Cancer Institute (NCI), Zentalis
Uterine Serous Carcinoma, Uterine Carcinoma, Uterine Cancer
01/26
01/27
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active, not recruiting
2
102
Europe, US, RoW
ZN-c3, azenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
04/25
10/25
NCT06015659: ZN-c3 + Gemcitabine in Pancreatic Cancer

Recruiting
2
34
US
Zentalis, Zn-c3, KP-2638, azenosertib, C29H34N8O2., Gemzar, Gemcitabine hydrochloride, FF 10832, LY188011, C9H11F2N3O4 - HCl
Brandon Huffman, Lustgarten Foundation, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc, Stand Up To Cancer
Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
06/26
06/27
ZN-c3-003, NCT04833582 / 2021-000021-27: A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma

Active, not recruiting
1/2
84
Europe, US
ZN-c3, Gemcitabine, Gemzar
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Osteosarcoma
08/23
12/23
ZN-c3-006, NCT05198804: A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Active, not recruiting
1/2
117
Europe, US
ZN-c3, Niraparib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Ovarian Cancer, Platinum-resistant Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
05/25
05/25
ZAP-IT, NCT06351332: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Recruiting
1/2
78
US
Azenosertib, ZN-c3, KP-2638, Carboplatin, C6H12N2O4Pt, platinum, diammine[1,1-cyclobutanedicarboxylato(2-)- O,O']-, (SP-4-2), Pembrolizumab, Keytruda, MK-3475, Humanized X PD-1-mAB (H409A11) IgG4, C6504H10004N1716O2036S46
Filipa Lynce, MD, Merck Sharp & Dohme LLC, Zentalis Pharmaceuticals
Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer, Hormone Receptor Negative Malignant Tumor Breast Triple, HER2-negative Breast Cancer
03/27
09/29
NCT05682170: Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

Jul 2023 - Dec 2023: Preliminary data from trial in combination with ZN-d5 for r/r/ AML
Recruiting
1/2
95
US
ZN-d5 ZN-c3, Study Drug, ZN-c3
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Acute Myeloid Leukemia (AML)
03/25
02/26
ZN-c3-016, NCT05743036: ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

Hourglass Jan 2023 - Mar 2023 : Initiation of P1/2 dose escalation study of ZN-c3 in combination with encorafenib & cetuximab in patients with BRAF V600E-mutated metastatic CRC
Recruiting
1/2
82
Europe, US, RoW
ZN-c3, Encorafenib, BRAFTOVI®, Cetuximab, ERBITUX®
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc, Pfizer
Metastatic Colorectal Cancer
08/26
09/26

Download Options